LDS/Medical Tests/Neisseria gonorrhoeae Ciprofloxacin Susceptibility Testing, PlexPrime GC+gyrA(550)

Neisseria gonorrhoeae Ciprofloxacin Susceptibility Testing, PlexPrime GC+gyrA(550)

The PlexPrime GC+gyrA(550) kit is a single-well, multiplex assay designed for simultaneous detection of the following targets: opa and porA genes (N. gonorrhoeae-specific markers), gyrA S91F mutation (associated with ciprofloxacin resistance), gyrA S91 wild-type (associated with ciprofloxacin susceptibility) to detect N. gonorrhoeae resistance to ciprofloxacin in persistent or recurrent infections.

Neisseria gonorrhoeae (GC) is the etiological agent of Gonorrhea, which is one of the most common sexually transmitted infections (STIs) globally, with increasing antimicrobial resistance posing a significant public health challenge. Early detection and susceptibility testing are essential for effective treatment and infection control. Antimicrobial resistant GC is a global public health concern, and standard management using empiric treatment is being challenged by the spread of resistance and limited alternate treatment options. Individualized treatment guided by antibiotic susceptibility information has been proposed as a strategy to re-instigate the use of antibiotics no longer recommended for empiric treatment, while also conserving last-line therapies.

Ciprofloxacin, a fluoroquinolone antibiotic, is an excellent option for individualized treatment. While it was abandoned from empirical use in most regions from the 2000’s , large proportions of gonorrhoeae cases remain susceptible. In addition, the gyrA S91 wild type and gyrA S91F mutation markers are highly predictive of ciprofloxacin susceptibility and resistance, respectively. Molecular detection of the gyrA S91 wild type and gyrA S91F mutation markers may be used to guide effective ciprofloxacin treatment in patients with susceptible infections.

  • Detection of N. gonorroeae strains resistance to ciprofloxacin in persistent infections
  • Optimization of treatment plans based on susceptibility results
  • Reduction in unnecessary use of last-line antibiotics
Positive opa and porA result: Indicates the presence of N. gonorrhoeae DNA. Positive gyrA S91 mutation result: Associated with resistance to ciprofloxacin (refer to CDC guidelines for treatment recommendations). Negative gyrA S91 mutation result: Associated with susceptibility to ciprofloxacin (refer to CDC guidelines for treatment recommendations). Results must always be interpreted in the context of the patient's clinical presentation, history, and CDC treatment guidelines.

N. gonorrhoeae not detected (Negative) N. gonorrhoeae detected, gyrA mutation not detected

Multiplex Real-Time- Polymerase Chain Reaction.

Vaginal swab, Urine, Liquid Cytology (ThinPrep, SurePath).

Stability

Vaginal Swab (Aptima Swab, UTM, M4 and other method specific transport media)

  • Ambient: 2-3 days
  • Refrigerated: 7 days
  • Frozen: >1 month

Liquid Cytology (ThinPrep, SurePath)

  • Ambient: 1 month
  • Frozen: up to 1 year
Neisseria gonorrhoeae culture, Chlamydia trachomatis by molecular, Trichomonas vaginalis by molecular.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login